The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity

Abstract

Iron (Fe) chelators are used clinically for the treatment of Fe overload disease. This study examined the potential of Fe chelators to prevent isoprenaline (ISO) cardiotoxicity.

In vitro and in vivo studies were used to test two chelators - desferrioxamine (DFO) and the lipophilic ligand, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone (PCTH). The study demonstrates that PCTH reduced ISO-induced cardiotoxicity in vitro and in vivo, demonstrating that Fe plays a role, in part, in the pathology observed.